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Chronic heart failure (HF) is a major public health problem, associated with high mortality, frequent hospitalization, 
and large cost burden to the healthcare system.1 Strategies 
to ameliorate this condition have focussed predominantly on 
blockade of key neurohormonal systems activated in this setting 
(eg, the renin–angiotensin–aldosterone1,2 and sympathetic 
nervous systems).1 Mineralocorticoid receptor antagonists 
(MRAs) have been demonstrated to be beneficial in patients 
with HF and severe symptoms in RALES3 (Randomized 
Aldactone Evaluation Study) and more recently in mild (New 
York Heart Association class II) patients in the EMPHASIS-HF 
(Eplerenone in Mild Patients Hospitalization and Survival 
Study in Heart Failure) study.4 In EMPHASIS-HF, patients 
were receiving standard HF therapies, that is, angiotensin-
converting enzyme inhibitors (ACEi) and angiotensin receptor 
blockers (ARBs), as well as β-blockers, as background therapy. 
Patients were considered well treated with these medications, 
at least in terms of the percent receiving these agents. However, 
for whatever reason, not all patients were receiving high doses 
of these therapies. It is of both therapeutic and mechanistic 
interest to evaluate the impact of eplerenone in patients who 
are receiving optimal (ie, high dose) background therapies to 
determine whether the beneficial effects observed in the overall 
study are preserved or diminished in this particular setting.
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Background—In EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure), 
eplerenone significantly reduced major cardiovascular events versus placebo in 2737 patients with mild symptoms of 
heart failure and an ejection fraction of <35%, in addition to recommended therapy. However, it is not known whether 
such benefits were preserved in patients receiving optimal background drug therapy, that is, high doses of angiotensin-
converting enzyme inhibitor (ACEi, or angiotensin receptor blocker), β-blocker, or both drug classes.
Methods and Results—We further analyzed EMPHASIS-HF according to the use and dose of these background drug classes. 
Patients receiving ≥50% of target dose were considered to be receiving high doses; patients on <50% or no drug comprised 
the low-dose group. The primary end point of the study (cardiovascular death/heart failure hospitalization), as well as all-
cause mortality, was evaluated in this way. The beneficial clinical effects of eplerenone (as observed in the main study) were 
preserved for the EMPHASIS-HF primary end point in patients receiving higher doses of ACEi or angiotensin receptor blocker, 
β-blocker, or both (hazard ratio for eplerenone versus placebo, ACEi/angiotensin receptor blocker: high dose, 0.67; low dose, 
0.65; β-blockers: high dose, 0.55; low dose, 0.72; both ACEi/angiotensin receptor blocker and β-blocker: high dose, 0.59; low 
dose, 0.68; P value for interaction 0.80, 0.15, and 0.53, respectively), as well as for all-cause mortality. There were no major 
safety issues, except a borderline increased risk of hypotension with eplerenone in those on high-dose ACEi or ACEi/β-blocker.
Conclusions—Eplerenone provides substantial benefit on major events (with an acceptable safety profile) in patients with 
mild symptoms of systolic heart failure, even in those already receiving high doses of standard background therapies.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00232180.   
(Circ Heart Fail. 2013;6:711-718.)
Key Words: ACE inhibitor ■ aldosterone ■ angiotensin receptor blocker ■ β-blocker ■ eplerenone ■ heart failure
Clinical Benefit of Eplerenone in Patients With Mild 
Symptoms of Systolic Heart Failure Already Receiving 
Optimal Best Practice Background Drug Therapy
Analysis of the EMPHASIS-HF Study
Henry Krum, MBBS, PhD; Harry Shi, MS; Bertram Pitt, MD; John McMurray, MD;  
Karl Swedberg, MD, PhD; Dirk J. van Veldhuisen, MD, PhD; John Vincent, MB, PhD;  
Stuart Pocock, PhD; Faiez Zannad, MD, PhD; for the EMPHASIS-HF Study Group
11  by guest on June 29, 2017
http://circheartfailure.ahajournals.org/
D
ow
nloaded from
 
712  Circ Heart Fail  July 2013
Accordingly, we conducted a subgroup analysis of 
EMPHASIS-HF to examine major clinical outcomes of 
EMPHASIS-HF according to background dose of ACEi (and 
ARB), β-blocker, and both classes of drug.
Methods
Study Patients
All randomized patients from the EMPHASIS-HF study contributed 
to this subgroup analysis. The characteristics of these patients have 
been well described previously, as have the inclusion and exclusion 
criteria of the study.5
Briefly, to qualify for randomization in EMPHASIS-HF, patients 
had to be >55 years of age, have New York Heart Association class 
II symptoms, and an ejection fraction of no more than 30% (or 
30%–35% if QRS duration >130 ms), as well as receiving standard 
background HF therapy, comprising ACEi, ARB (or both), as well as 
β-blocker at recommended or maximal tolerated doses. Investigators 
were encouraged to uptitrate patients to highest stable doses of these 
therapies before randomization into the EMPHASIS-HF study.
Dosing Equivalent of Background Drugs
A target daily dose was established based on approved dose ranges 
and targets for individual ACEi, ARBs, and β-blockers (Table 1). The 
percentage daily dose of the individual patient was determined based 
on the total daily dose expressed as a percentage of the target daily 
dose of each agent being taken at baseline (before randomization). 
From this, outcomes according to patients receiving less or greater 
than 50% target dose were derived.
Study Outcomes
Assessment was made according to target dose, with patients receiv-
ing ≤50% of target daily dose considered to be receiving low dose 
and >50% high dose. Patients not taking a particular drug class were 
considered to be in the low-dose group. Groups evaluated separately 
were as follows:
•	 ACEi (and ARB) ≥50%, versus <50% target dose.
•	 β-blocker ≥50%, versus <50% target dose.
•	 Both ACEi and β-blocker ≥50%, versus at least one of ACEi or 
β-blocker <50% target dose.
Outcomes evaluated according to background drug dose were the 
EMPHASIS-HF primary end point (time to first event of cardio-
vascular [CV] death or HF hospitalization) and all-cause mortality.
In addition, relevant safety end points (frequency of hyperkalemia, 
estimated glomerular filtration rate [eGFR], clinical hypotension) 
were also evaluated according to background drug dose.
Statistical Analysis
The following analyses are performed on the background drug groups 
defined above. Descriptive statistics are summarized for the baseline 
data, including demographics and relevant baseline data. The efficacy 
analyses on the primary end point (HF hospitalization/CV death) and 
all-cause mortality are performed using a Cox proportional hazards 
Table 1. Dosage Equivalence of ACE Inhibitors, ARBs,  
and β-Blockers as Used in the Present Analysis
Total Daily 
Dose, mg
ACE inhibitor
 Captopril 150
 Enalapril 20
 Lisinopril 20
 Perindopril 10
 Ramipril 10
 Trandolapril 4
β-Blocker
 Bisoprolol 10
 Carvedilol 50
 Metoprolol succinate (CR/XL) 200
 Nebivolol 10
ARB
 Candesartan 32
 Valsartan 320
 Losartan 150
ACE indicates angiotensin-converting enzyme; ARB, angiotensin receptor 
blocker; CR, controlled release; and XL, extended release.
Table 2. Baseline Patient Characteristics According to Background Drug Dose: ACEi/ARB
ACEi≥50% Dose (N=1530) ACEi<50% Dose (N=1207)
Eplerenone (n=776) Placebo (n=754) Eplerenone (n=588) Placebo (n=619)
Age, y 68.6 68.6 68.7 68.7
Female, % 22.4 21.1 23.0 22.9
Ischemic HF, % 67.4 65.1 72.8 71.7
BMI, kg/m2 28.0 27.9 26.8 27.0
Systolic BP, mm Hg 127.0 126.3 120.8 121.0
Heart rate, bpm 72.5 72.7 75.1 73.7
LVEF, % 26.2 26.1 26.1 26.0
eGFR, mL/min per 1.732 72.1 70.6 69.9 70.1
Serum K+, meq/L 4.3 4.3 4.3 4.3
Device therapy, %
 Implantable cardioverter-defibrilator 12.6 12.2 13.6 14.9
 Cardiac resynchronization therapy 2.7 1.3 2.9 1.9
  Implantable cardioverter-defibrilator with cardiac 
resynchronization
4.9 6.4 6.1 8.2
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; bpm, beats per minute; eGFR, 
estimated glomerular filtration rate; HF, heart failure; and LVEF, left ventricular ejection fraction.
Overall P>0.05 between groups.
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model, including treatment, subgroup, and treatment by subgroup in-
teraction. In addition, the frequency of serum potassium ≥5.5 mmol/L 
and hypotension adverse event were analyzed using Fisher exact test, 
and eGFR and blood pressure data at end of study are also summarized.
Results
Main Study Results
The EMPHASIS-HF primary outcome (time to first event of 
CV death or HF hospitalization) occurred in 18.3% of patients 
in the eplerenone group compared with 25.9% in the placebo 
group (hazard ratio [HR], 0.63; 95% confidence interval, 0.54–
0.74; P<0.001). Death (all-cause) occurred in 12.5% of patients 
receiving eplerenone and in 15.5% of those receiving placebo 
(HR, 0.76; 95% confidence interval, 0.62–0.93; P=0.008). 
Eplerenone was overall well tolerated; however, there were 
increases compared with placebo (as expected) in rates of wors-
ened renal function, hyperkalemia, and hypotension. However, 
there were no differences between groups in rate of adverse 
events, leading to permanent withdrawal of study drug.
Baseline Patient Characteristics According  
to Background Drug Dose
Key patient characteristics, when subdivided according to 
background drug and dose, are summarized in Tables 2–4. 
Table 3. Baseline Patient Characteristics According to Background Drug Dose: β-Blocker
BB≥50% Dose (N=1081) BB<50% Dose (N=1656)
Eplerenone (n=536) Placebo (n=545) Eplerenone (n=828) Placebo (n=828)
Age, y 68.2 68.1 69.0 68.9
Female, % 22.0 19.8 23.1 23.3
Ischemic HF, % 65.7 65.1 72.3 70.0
BMI, kg/m2 28.5 28.3 26.9 27.0
Systolic BP, mm Hg 126.1 125.23 123.2 123.1
Heart rate, bpm 72.5 71.7 74.4 74.1
LVEF, % 26.0 26.2 26.2 26.0
eGFR, mL/min per 1.732 72.1 70.5 70.6 70.3
Serum K+, meq/L 4.3 4.3 4.3 4.3
Device therapy, %
 Implantable cardioverter-defibrilator 17.5 6.1 10.1 12.0
 Cardiac resynchronization therapy 2.4 2.6 3.0 1.0
  Implantable cardioverter-defibrilator with cardiac 
resynchronization
6.7 7.3 4.6 7.1
BMI indicates body mass index; BP, blood pressure; bpm, beats per minute; eGFR, estimated glomerular filtration rate; HF, heart failure; and LVEF, left ventricular 
ejection fraction.
Overall P>0.05 between groups.
Table 4. Baseline Patient Characteristics According to Background Drug Dose: ACEi/ARB and β-Blocker
ACEi and BB ≥50%  
Dose (N=736)
At Least One of ACEi or BB<50%  
Dose (N=2001)
Eplerenone (n=371) Placebo (n=365) Eplerenone (n=993) Placebo (n=1008)
Age, y 68.1 67.9 68.9 68.9
Female, % 22.9 19.5 22.6 22.8
Ischemic HF, % 64.4 63.3 71.7 69.8
BMI, kg/m2 28.7 28.4 27.1 27.2
Systolic BP, mm Hg 127.9 126.5 123.0 123.0
Heart rate, bpm 71.9 71.9 74.3 73.7
LVEF, % 26.0 26.2 26.2 26.0
eGFR, mL/min per 1.732 72.7 70.8 70.6 70.2
Serum K+, meq/L 4.3 4.3 4.3 4.3
Device therapy, %
 Implantable cardioverter-defibrilator 15.9 15.6 12.0 12.6
 Cardiac resynchronization therapy 2.4 2.5 2.9 1.3
  Implantable cardioverter-defibrilator with cardiac 
resynchronization
5.7 6.3 5.3 7.5
ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood pressure; bpm, beats per minute; eGFR, 
estimated glomerular filtration rate; HF, heart failure; and LVEF, left ventricular ejection fraction.
Overall P>0.05 between groups.
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In general, patients were well matched with regard to these 
key demographic characteristics, despite the number of 
patients in specific subgroups being relatively small in some 
circumstances.
Efficacy End Points According to  
Background Drug Dose
Table 5 summarizes the effect of eplerenone versus placebo on 
the study’s primary end point (CV death/HF hospitalization) 
according to dose of background neurohormonal antagonist 
drug therapy. Specifically, there was no significant difference 
in this outcome according to high (>50%) versus low dose 
of ACEi (or ARB), β-blocker, or both ACEi (or ARB) and 
β-blocker. P values for interaction between high and low 
doses for the EMPHASIS-HF primary end point were not 
significant. The HRs for eplerenone versus placebo for the 
EMPHASIS-HF primary end point were as follows: ACEi/
ARB: high dose, 0.67; low dose, 0.65; β-blockers: high 
dose, 0.55; low dose, 0.72; both ACEi/ARB and β-blocker: 
high dose, 0.59; low dose, 0.68. Kaplan–Meier plots for this 
outcome in patients receiving high- and low-dose background 
therapy are shown in Figures 1 to 3.
Table 6 summarizes the effect of eplerenone versus placebo 
on all-cause mortality according to dose of background 
neurohormonal antagonist drug therapy. Similar to the study’s 
primary end point, there was no significant difference in this 
outcome according to high (>50%) versus low dose of ACEi 
(or ARB), β-blocker, or both ACEi (or ARB) and β-blocker. 
P values for interaction between high and low doses for all-
cause mortality were not significant. The HRs for eplerenone 
versus placebo for all-cause mortality were as follows: ACEi/
ARB: high dose, 0.77; low dose, 0.79; β-blockers: high dose, 
0.71; low dose, 0.81; both ACEi/ARB and β-blocker: high 
dose, 0.83; low dose, 0.76.
Safety End Points According to  
Background Drug Dose
Table 7 summarizes the effect of eplerenone versus placebo 
on incident hyperkalemia according to dose of background 
neurohormonal antagonist drug therapy. As expected, there 
was a greater incidence of hyperkalemia in the eplere-
none group compared with placebo. However, there was 
little evidence of greater absolute rate of hyperkalemia 
events in patients receiving high doses versus low doses 
of background agents. Furthermore, there was no signifi-
cant interaction observed for HRs between high- and low-
dose background therapy for ACEi (or ARB), β-blocker, or 
both agents.
Table 8 summarizes the effect of eplerenone versus placebo 
on eGFR at end of study according to dose of background 
neurohormonal antagonist drug therapy. Overall, there was 
little difference in eGFR at end of study in the eplerenone 
group compared with placebo. Furthermore, there was little to 
no evidence of an increase in eGFR in patients receiving high 
doses versus low doses of background agents. Specifically, 
there was no significant interaction observed for HRs between 
high- and low-dose background therapy for ACEi (or ARB), 
β-blocker, or both agents.
Table 9 summarizes the effect of eplerenone versus pla-
cebo on the clinical adverse events of hypotension or postural 
hypotension at end of study according to dose of background 
neurohormonal antagonist drug therapy. There was over-
all no significant increased risk of this adverse event with 
Table 5. EMPHASIS-HF Primary End Point (CV Death/HF Hospitalization) According to Background Dose of Key  
Neurohormonal Agents
Eplerenone, % Placebo, % Hazard Ratio
P Value for Dose×Treatment 
Interaction
ACEi≥50% dose (n=1530) 131 (16.9) 181 (24.0) 0.67
ACEi<50% dose (n=1207) 118 (20.1) 175 (28.3) 0.65 0.80
BB≥50% dose (n=1081) 73 (13.6) 121 (22.2) 0.55
BB<50% dose (n=1656) 176 (21.3) 235 (28.4) 0.72 0.15
ACEi and BB≥50% dose (n=736) 51 (13.7) 78 (21.4) 0.59
At least one of ACEi or BB<50% dose (n=2001) 198 (19.9) 278 (27.6) 0.68 0.53
ACEi indicates angiotensin-converting enzyme inhibitor; BB, β-blocker; CV, cardiovascular; and HF, heart failure.
Table 6. All-Cause Mortality According to Background Dose of Key Neurohormonal Agents
Eplerenone, % Placebo, % Hazard Ratio
P Value for Dose×Treatment 
Interaction
ACEi≥50% dose (n=1530) 88 (11.3) 110 (14.6) 0.77
ACEi<50% dose (n=1207) 83 (14.1) 103 (16.6) 0.79 0.90
BB≥50% dose (n=1081) 56 (10.4) 74 (13.6) 0.71
BB<50% dose (n=1656) 115 (13.9) 139 (16.8) 0.81 0.58
ACEi and BB≥50% dose (n=736) 41 (11.1) 46 (12.6) 0.83
At least one of ACEi or BB<50% dose (n=2001) 130 (13.1) 167 (16.6) 0.76 0.70
ACEi indicates angiotensin-converting enzyme inhibitor; and BB, β-blocker.
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eplerenone versus placebo, irrespective of receiving high- and 
low-dose background therapy for ACEi (or ARB), β-blocker, 
or both agents.
Discussion
The present analysis examined whether the beneficial effects 
of eplerenone observed in the overall EMPHASIS-HF study 
were maintained in the subgroup of patients receiving optimal 
best practice background drug therapy comprising use of 
high-dose ACEi (or ARB) or β-blocker or both.
This analysis is of relevance to the drug management of 
systolic HF patients with New York Heart Association class II 
symptoms as well as being of considerable mechanistic inter-
est. ACEi and β-blockers are well established as mandatory 
life-saving background therapy in such patients.1 However, 
it is well established that not all patients are able to tolerate 
these medications, and those that do often cannot reach target 
doses of these therapies for reasons of intolerance and adverse 
events. In the EMPHASIS-HF study,4 77% of patients were 
receiving an ACEi, 19% ARB, and 94% either agent or both. 
Similarly, 87% of patients were receiving β-blockers.
Predefined subgroup analysis has determined that patients 
receiving these background therapies derived similar benefit 
with eplerenone as regards the primary study end point 
(CV death or HF hospitalization) versus those who were 
not receiving these agents.4 However, analysis according to 
dosing of these agents has not been previously performed 
within the EMPHASIS-HF cohort. This is of importance as 
the question arises as to whether the benefits of eplerenone 
are maintained in the setting of higher doses of these agents. 
Alternatively, it may be argued that the same outcome benefit 
may be achieved by simply increasing the dose of background 
medication. When use of ivabradine additional to β-blockers 
was examined in this way in SHIFT (Systolic Heart failure 
treatment with If inhibitor ivabradine Trial),6 the magnitude 
of benefit of ivabradine in patients receiving >50% of dose 
of β-blocker was substantially reduced in comparison with 
the overall population. In contrast, the present analysis of 
EMPHASIS-HF demonstrates that the HRs generated for 
CV death/HF hospitalization or for all-cause mortality with 
the MRA eplerenone were of similar magnitude above and 
below 50% target dose for ACEi (or ARB) or β-blocker. 
Furthermore, this benefit was maintained in patients who had 
>50% of dosing for both background agents. These findings 
support the concept that addition of an MRA to background 
high-dose ACEi and β-blockers provides substantial 
additional clinical outcome benefit. Although a head-to-head 
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Figure 1. Effect of eplerenone versus placebo on the EMPHASIS-HF study primary end point (cardiovascular [CV] death/heart failure [HF] 
hospitalization) according to background angiotensin-converting enzyme inhibitor (or angiotensin receptor blocker) dose (above or below 
50% of target dose). CI indicates confidence interval; and HR, hazard ratio.
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hazard ratio.
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study of increasing dose of these background agents versus 
the addition of eplerenone has not yet been performed, these 
findings would suggest that eplerenone may be the preferred 
strategy in this regard. However, this was not formally tested 
in the EMPHASIS-HF study nor has it been studied in other 
trials of MRAs in HF.
As mentioned, this analysis is also of considerable mecha-
nistic interest and importance. As mentioned, there was main-
tenance of the overall benefit observed with eplerenone in 
the subgroup receiving high-dose ACEi and β-blocker. These 
findings suggest that the aldosterone inhibitory effect of a con-
ventional strategy is either suboptimal or associated with clin-
ically relevant aldosterone escape.7 These findings support the 
need for direct mineralocorticoid receptor blockade to maxi-
mize renin–angiotensin–aldosterone blockade and associated 
clinical benefits. However, serum aldosterone levels were not 
analyzed in the present analysis, so this remains a hypothesis 
still to be formally tested.
The results of this analysis are also of relevance to the 
ongoing debate regarding how best to maximize the bene-
fits of neurohormonal blockade in various CV settings, but 
specifically in systolic chronic HF. It is, however, uncertain 
whether 2 or 3 (or more) neurohormonal blocking agents are 
the optimal approach when added to standard background 
treatment.8 The data have been mixed in this regard. For exam-
ple, the benefits of adding the ARB candesartan seemed to be 
preserved, irrespective of dose of ACEi background therapy 
in CHARM (Conduction in Heart Failure: Assessment of 
Reduction in Mortality and Morbidity)-Added.9 In contrast, 
in Val-HeFT (Valsartan Heart Failure Trial), the benefi-
cial effects of valsartan were progressively attenuated with 
increasing dose of background ACEi.10 The data seem more 
clear-cut with MRA therapy; in both EPHESUS (Eplerenone 
Post-Acute Myocardial Infarction Heart Failure Efficacy and 
Survival Study)11 and now EMPHASIS-HF, the efficacy ben-
efits of this strategy seem to be preserved in the setting of 
maximized background therapy.
With regard to safety, the present subgroup analysis eval-
uated hyperkalemia and renal function according to use of 
eplerenone versus placebo and background ACEi (or ARB) 
or β-blocker dose (as well as for both background agents 
combined). The findings of this subgroup analysis would 
suggest that 2 of the most feared adverse events of MRAs 
(hyperkalemia, worsened renal function) do not occur 
with significantly greater frequency when added to high-
dose (versus low-dose) background neurohormonal drug 
therapy. Analysis of the impact of background neurohor-
monal drug dose on incidence of hypotension or postural 
hypotension does however suggest a borderline increase in 
risk of this adverse event in patients receiving high-dose 
(>50% dose) ACEi or ACEi combined with β-blocker at 
high dose.
Given that HF guidelines worldwide recommend highest 
tolerated dose of ACEi and β-blockers, the findings of the 
present subgroup analysis suggest that efficacy of eplerenone 
is maintained additional to these recommended drugs and 
doses and that safety is not unduly compromised in this setting 
(ie, patients with systolic HF and mild symptoms).
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Figure 3. Effect of eplerenone versus placebo on the EMPHASIS-HF study primary end point (cardiovascular [CV] death/heart failure [HF] 
hospitalization) according to background angiotensin-converting enzyme inhibitor (or angiotensin receptor blocker) and β-blocker dose 
(above or below 50% of target dose). CI indicates confidence interval; and HR, hazard ratio.
Table 7. Incident Hyperkalemia (Any Occurrence of Serum Potassium>5.5 mmol/L) According to Background Dose of Key 
Neurohormonal Agents
Eplerenone, % Placebo, % P Value by Fisher Exact Test
ACEi≥50% dose (n=1530) 12.6 7.0 0.0003
ACEi<50% dose (n=1207) 10.8 7.4 0.043
BB≥50% dose(n=1081) 10.8 7.9 0.14
BB<50% dose (n=1656) 12.5 6.7 <0.0001
ACEi and BB≥50% dose (n=736) 11.2 6.5 0.027
At least one of ACEi or BB<50% dose (n=2001) 12.1 7.4 0.0006
ACEi indicates angiotensin-converting enzyme inhibitor; and BB, β-blocker.
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In summary, the present subgroup analysis of 
EMPHASIS-HF has found that MRA eplerenone provided 
substantial clinical benefit and acceptable safety, even in the 
setting of high-dose background ACEi (or ARB) or β-blocker 
or both. Thus, use of eplerenone should be strongly consid-
ered, irrespective of dose of background neurohormonal 
antagonist therapy in systolic HF patients with mild (New 
York Heart Association class II) symptoms.
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Table 9. Incident Hypotension or Postural Hypotension According to Background Dose of Key Neurohormonal Agents
Subgroup Adverse Event Eplerenone n/N (%) Placebo n/N (%)
P Value Fisher 
Exact Test
ACE inhibitors
>50% target dose
Hypotension 30/772 (3.9) 17/752 (2.3) 0.076
Orthostatic hypotension 6/772 (0.8) 3/752 (0.4) 0.507
Overall 35/772 (4.5) 20/752 (2.7) 0.055
ACE inhibitors
<50% target dose
Hypotension 16/588 (2.7) 20/617 (3.2) 0.616
Orthostatic hypotension 1/588 (0.2) 7/617 (1.1) 0.070
Overall 17/588 (2.9) 25/617 (4.1) 0.346
β-Blockers
>50% target dose
Hypotension 16/533 (3.0) 12/543 (2.2) 0.449
Orthostatic hypotension 5/533 (0.9) 6/543 (1.1) 0.999
Overall 20/533 (3.8) 17/543 (3.1) 0.618
β-Blockers
<50% target dose
Hypotension 30/827 (3.6) 25/826 (3.0) 0.584
Orthostatic hypotension 2/827 (0.2) 4/826 (0.5) 0.452
Overall 32/827 (3.9) 28/826 (3.4) 0.694
ACE inhibitors ≥50% target dose and 
β-blockers ≥50% target dose
Hypotension 13/369 (3.5) 5/363 (1.4) 0.092
Orthostatic hypotension 5/369 (1.4) 2/363 (0.6) 0.451
Overall 17/369 (4.6) 7/363 (1.9) 0.060
ACE inhibitors <50% target dose and 
β-blockers <50% target dose
Hypotension 33/991 (3.3) 32/1006 (3.2) 0.900
Orthostatic hypotension 2/991 (0.2) 8/1006 (0.8) 0.107
Overall 35/991 (3.5) 38/1006 (3.8) 0.812
ACE indicates angiotensin-converting enzyme.
Table 8. eGFR at End Study According to Background Dose of Key Neurohormonal Agents
Eplerenone, % 
Mean SD
Placebo, %
Mean SD
ACEi≥50% dose (n-1530) 68.6 22.3 68.9 20.9
ACEi<50% dose (n=1207) 68.3 24.2 69.8 25.0
BB≥50% dose (n=1081) 69.0 22.2 69.1 22.2
BB<50% dose (n=1656) 68.1 23.8 69.4 23.2
ACEi and BB≥50% dose (n=736) 68.4 22.2 69.1 20.1
At least one of ACEi or BB<50% dose (n=2001) 68.5 23.6 69.4 23.7
ACEi indicates angiotensin-converting enzyme inhibitor; BB, β-blocker; and eGFR, estimated glomerular filtration rate.
All P values by Fisher exact test >0.05 for eplerenone vs placebo.
 by guest on June 29, 2017
http://circheartfailure.ahajournals.org/
D
ow
nloaded from
 
718  Circ Heart Fail  July 2013
References
 1. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, 
Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, 
Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske 
BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic 
P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A; ESC 
Committee for Practice Guidelines (CPG), Bax JJ, Baumgartner H, 
Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D, 
Hoes A, Kirchhof P, Knuuti J, Kolh P, McDonagh T, Moulin C, Popescu 
BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Torbicki A, Vahanian 
A, Windecker S; Document Reviewers, McDonagh T, Sechtem U, Bonet 
LA, Avraamides P, Ben Lamin HA, Brignole M, Coca A, Cowburn P, 
Dargie H, Elliott P, Flachskampf FA, Guida GF, Hardman S, Iung B, 
Merkely B, Mueller C, Nanas JN, Nielsen OW, Orn S, Parissis JT, 
Ponikowski P. ESC Guidelines for the diagnosis and treatment of acute 
and chronic heart failure 2012: The Task Force for the Diagnosis and 
Treatment of Acute and Chronic Heart Failure 2012 of the European 
Society of Cardiology. Developed in collaboration with the Heart Failure 
Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803–869.
 2. McMurray JJ. CONSENSUS to EMPHASIS: the overwhelming evi-
dence which makes blockade of the renin-angiotensin-aldosterone sys-
tem the cornerstone of therapy for systolic heart failure. Eur J Heart Fail. 
2011;13:929–936.
 3. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, 
Wittes J. The effect of spironolactone on morbidity and mortality in pa-
tients with severe heart failure. Randomized Aldactone Evaluation Study 
Investigators. N Engl J Med. 1999;341:709–717.
 4. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, 
Shi H, Vincent J, Pocock SJ, Pitt B; EMPHASIS-HF Study Group. 
Eplerenone in patients with systolic heart failure and mild symptoms. N 
Engl J Med. 2011;364:11–21.
 5. Zannad F, McMurray JJ, Drexler H, Krum H, van Veldhuisen DJ, 
Swedberg K, Shi H, Vincent J, Pitt B. Rationale and design of the 
Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart 
Failure (EMPHASIS-HF). Eur J Heart Fail. 2010;12:617–622.
 6. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, 
Lerebours G, Tavazzi L; SHIFT Investigators. Ivabradine and outcomes 
in chronic heart failure (SHIFT): a randomised placebo-controlled study. 
Lancet. 2010;376:875–885.
 7. Struthers AD. The clinical implications of aldosterone escape in conges-
tive heart failure. Eur J Heart Fail. 2004;6:539–545.
 8. Massie BM. Neurohormonal blockade in chronic heart failure. How much 
is enough? Can there be too much? J Am Coll Cardiol. 2002;39:79–82.
 9. McMurray JJ, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson 
EL, Earle S, Olofsson B, Ostergren J, Yusuf S, Swedberg K, Pfeffer MA; 
CHARM Investigators. Relationship of dose of background angioten-
sin-converting enzyme inhibitor to the benefits of candesartan in the 
Candesartan in Heart failure: Assessment of Reduction in Mortality and 
morbidity (CHARM)-Added trial. Am Heart J. 2006;151:985–991.
 10. Krum H, Carson P, Farsang C, Maggioni AP, Glazer RD, Aknay N, 
Chiang YT, Cohn JN. Effect of valsartan added to background ACE in-
hibitor therapy in patients with heart failure: results from Val-HeFT. Eur 
J Heart Fail. 2004;6:937–945.
 11. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman 
R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial 
Infarction Heart Failure Efficacy and Survival Study Investigators. 
Eplerenone, a selective aldosterone blocker, in patients with left ventric-
ular dysfunction after myocardial infarction. N Engl J Med. 2003;348: 
1309–1321.
Eplerenone has been shown to be of benefit in patients with mild symptoms of systolic heart failure in the EMPHASIS-HF 
(Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure) study. However, it is uncertain whether 
those clinical benefits remain significant when the agent is added to best practice background therapy, that is, high doses 
of angiotensin-converting enzyme inhibitor (or angiotensin receptor blocker), β-blocker, or both. We therefore analyzed 
major outcomes in EMPHASIS-HF according to dose of these key background heart failure therapies. The findings were 
that major clinical benefits were generally preserved with eplerenone even when added to higher doses of these background 
therapies. These findings should also be considered in the context of the safety profile of addition of eplerenone to high-dose 
background therapy. In general, safety was found to be acceptable. The clinical implication of these findings is that, even in 
patients in whom high doses of background therapies are used, a mineralocorticoid receptor antagonist is of benefit in this 
patient population.
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